ASX Small-Cap Market Movers on Monday

Sonal Goyal

23 March 2026 04:50 PM AEDT

Image Source: shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

The Australian Securities Exchange (ASX) saw notable gains among small-cap stocks today, driven by strategic agreements, acquisitions, and project developments. Key movers include Energy Technologies Limited (ASX:EGY), Calix Limited (ASX:CXL), and Cyclopharm Limited (ASX:CYC).

Energy Technologies Limited (ASX:EGY) – +23.53%

Share Price: $0.021 (+$0.004)
Market Capitalisation: $8.49M

Today’s Catalyst: Acquisition of Maradin Ltd’s Laser Optical Engineering IP Portfolio via its wholly owned subsidiary, Cogenic Pty Limited.

Strategic Impact:

Positions Cogenic at a prototype-ready stage for full laser projection optical engineering.
Targets markets in defense, aerospace, virtual and augmented reality, and lifestyle applications.
Acquisition adds 14 global patents and a fully operational development team, accelerating commercialization.

Revenue & Funding:

Acquisition funded under current facilities (~AUD 953,872).
Payment structured over 18 months, allowing staged integration.

Market Reaction: The 23.5% jump reflects investor optimism about Cogenic’s commercial potential and the broader applicability of laser optical technology in high-growth markets.

Calix Limited (ASX:CXL) – +0.88%

Share Price: $0.570 (+$0.005)
Market Capitalisation: $121.87M

Today’s Catalyst: Execution of a toll processing agreement with Green360 Technologies (ASX: GT3) to produce calcined clay for low-carbon cement.

Strategic Impact:

Toll processing up to 30,000 tonnes per annum at Calix’s Bacchus Marsh Technology Centre.
Supports Green360’s Eco-clay low-carbon cement product.
No capital expenditure required from Calix; Green360 covers necessary upgrades.
Aligns with global trends in industrial decarbonization and sustainable cement production.

Revenue Outlook:

Full throughput could generate multi-million AUD annual revenues, starting FY26.
Strengthens operational synergies with existing magnesia operations.

Market Reaction: Investors responded positively to the revenue potential and low-risk growth strategy.

Cyclopharm Limited (ASX:CYC) – +4.17%

Share Price: $0.750 (+$0.030)
Market Capitalisation: $86.97M

Today’s Catalyst: Multi-site agreement with the University of Pennsylvania Health System (UPHS) for 11 Technegas® installations.

Strategic Impact:

Two immediate installations at high-volume sites; nine additional sites to follow.
Technegas® revenue model includes installation, annual service, and per-patient consumables.
Expands Cyclopharm’s footprint in the US Mid-Atlantic and Northeast, targeting system-wide adoption in Integrated Delivery Networks (IDNs).

Clinical & Commercial Benefits:

Extends Technegas® use beyond pulmonary embolism, into COPD, asthma, oncology, and interventional procedures.
Establishes a reference cluster in a top-tier academic health system, enhancing credibility and adoption potential.

Market Reaction: Investors rewarded the stock for scalable recurring revenue potential and strategic US expansion.

Market Overview: Key Takeaways

Small-cap innovation drives gains: All three gainers are executing strategic growth initiatives, including technology acquisitions (EGY), partnerships for sustainable products (CXL), and US market expansion (CYC).
Investor sentiment favors future revenue visibility: Contracts and acquisitions that signal recurring revenue streams and tangible market adoption continue to attract attention.
Sector diversification: Gains spanned clean tech, industrial decarbonization, and radiopharmaceuticals, showing that small-cap investors are increasingly targeting high-growth, innovation-driven niches.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.